source
- Intellia CRISPR drug succeeds in late-stage study against rare swelling disorderThe findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of intense investor debate.BioPharma Dive · 3mo ago↗ source
- Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitorEli Lilly keeps putting its GLP-1 windfall to use. On Monday, the anti-obesity drugmaker announced its latest deal to expand its pipeline of future drugs, saying it would spend as much asEndpoints · 3mo ago↗ source
- Compass Therapeutics unveils key secondary endpoint results from pivotal biliary tract cancer trialA year after it reported a Phase 2/3 success, Compass Therapeutics on Monday revealed further results for its closely watched bispecific antibody in second-line biliary tract cancer. While the inve…